Nexstim05.11.18
Nexstim Plc, the targeted neuromodulation company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic application, announced that it is launching its Navigated Brain Therapy (NBT) system in the US for the treatment of Major Depressive Disorder (MDD) at the Clinical TMS (transcranial magnetic stimulation) Society Annual Meeting in New York following FDA clearance for the device in November last year.
The Clinical TMS Society Annual Meeting takes place from 11-13 May, and is a focused conference, bringing together over 500 participants including current and new TMS practitioners. Nexstim will introduce and demonstrate the use of its NBT system at the event and will also participate in a PULSES workshop session to train physicians in the use of the system to treat depression.
The system has been cleared by the FDA for the treatment of MDD, a recurrent and frequently chronic disorder with significant unmet clinical need. Approximately 10 million Americans suffer from Major Depressive Disorder (MDD) annually and 35 percent of patients treated with anti-depressant drugs fail to respond to this method of treatment.
Nexstim’s NBT therapy provides personalized non-invasive neurostimulation therapy as an alternative to sub-optimal pharmacologic treatments via its SmartFocus TMS technology.
To drive the uptake of its highly differentiated system, Nexstim is expanding its US based field organization to support sales and service, led by Steve Beller, vice president and general manager, North America. The company will also establish a US TMS Therapy Clinical Advisory Panel comprising physicians who adopt the NBT system, to provide advice and feedback on use of the system, including potential new therapeutic applications.
The Clinical TMS Society Annual Meeting takes place from 11-13 May, and is a focused conference, bringing together over 500 participants including current and new TMS practitioners. Nexstim will introduce and demonstrate the use of its NBT system at the event and will also participate in a PULSES workshop session to train physicians in the use of the system to treat depression.
The system has been cleared by the FDA for the treatment of MDD, a recurrent and frequently chronic disorder with significant unmet clinical need. Approximately 10 million Americans suffer from Major Depressive Disorder (MDD) annually and 35 percent of patients treated with anti-depressant drugs fail to respond to this method of treatment.
Nexstim’s NBT therapy provides personalized non-invasive neurostimulation therapy as an alternative to sub-optimal pharmacologic treatments via its SmartFocus TMS technology.
To drive the uptake of its highly differentiated system, Nexstim is expanding its US based field organization to support sales and service, led by Steve Beller, vice president and general manager, North America. The company will also establish a US TMS Therapy Clinical Advisory Panel comprising physicians who adopt the NBT system, to provide advice and feedback on use of the system, including potential new therapeutic applications.